Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114)

Journal of Clinical Oncology

Volumn 27, Issue 12, 2009, Pages 1956-1962

  Schwartz, Gary K ^a   Winter, Kathryn ^b   Minsky, Bruce D ^c   Crane, Christopher ^d   Thomson, P John ^e   Anne, Pramila ^f   Gross, Howard ^g   Willett, Christopher ^a   Kelsen, David ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Radiation Therapy Oncology Group   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Latter Day Saints Hospital   (United States)

^f Dayton Community Clinical Oncology Program   (United States)

^g DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLEEDING TENDENCY; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG SAFETY; EYE TOXICITY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OTOTOXICITY; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; STOMACH CANCER; SURVIVAL RATE; THERAPY EFFECT; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; RISK FACTORS; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 65349103986     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.3745     Document Type: Article

References (13)

1. Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725- 730, 2001
2. Ajani JA, Ilson DH, Daugherty K, et al: Activity of paclitaxel (Taxol) in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86:1086-1091, 1994
3. Ajani JA, Fairweather J, Pazdur R, et al: Phase II study of Taxol in patients with untreated metastatic gastric carcinoma. Cancer J Sci Am 4:269-274, 1998
4. Safran H, Wanebo HJ, Hesketh PJ, et al: Paclitaxel and concurrent radiation for gastric cancer. Int J Radiat Oncol Biol Phys 46:889-894, 2000
5. Ilson DH, Ajani JA, Bhalla K, et al: A phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16:1826-1834, 1998
6. Brenner B, Ilson D, Minsky B, et al: A phase I trial of combined-modality therapy for localized esophageal cancer: Escalating doses of continuousinfusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 22:45-52, 2004
7. Ajani JA, Mansfield PF, Crane CH, et al: Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: Degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 23:1237-1244, 2005
8. Zelen M: The randomization and stratification of patients to clinical trials. J Chronic Disease 27: 365-375, 1994
9. Kaplan EL, Meier P: Non-parametric estimation from incomplete observation. J Am Stat 53:457- 481, 1958
10. Roth AD, Fazio N, Stupp R, et al: Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: A randomized phase II trial of the Swiss Group for Clinical Cancer Res. J Clin Oncol 25:3217-3223, 2007
11. Leong T, Michael M, Foo K, et al: Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation. Br J Cancer 89:1433-1438, 2003
12. Ajani JA, Moiseyenko VM, Tjulandin S, et al: Group Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: The V-325 Study Group. J Clin Oncol 25:3205- 3209, 2007
13. Van Cutsem E, Moiseyenko VM, et al: Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 24: 4991-4997, 2006